Health Catalyst Analyst Ratings
Buy Rating on Health Catalyst: Strategic Innovation and Client Growth Poised to Drive Performance
Barclays Issues a Buy Rating on Health Catalyst (HCAT)
RBC Capital Remains a Hold on Health Catalyst (HCAT)
Maintaining Buy Rating on Health Catalyst: Strong Sales Pipeline and Margin Outlook Offset Slower Growth Forecast
Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10
Health Catalyst Analyst Ratings
Optimistic Outlook: Health Catalyst's Growth and Profitability Potential Affirm Buy Rating
Stifel Nicolaus Remains a Hold on Health Catalyst (HCAT)
Piper Sandler Sticks to Their Buy Rating for Health Catalyst (HCAT)
Health Catalyst (HCAT) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)
Stifel Nicolaus Sticks to Its Hold Rating for Health Catalyst (HCAT)
Health Catalyst Analyst Ratings
Analysts Conflicted on These Healthcare Names: Karuna Therapeutics (KRTX) and Health Catalyst (HCAT)
Health Catalyst (HCAT) Gets a Buy From Piper Sandler
BTIG Sticks to Their Buy Rating for Health Catalyst (HCAT)
Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11
Health Catalyst Analyst Ratings
Piper Sandler Maintains Overweight on Health Catalyst, Raises Price Target to $12
No Data